Johnson & Johnson (JNJ) Receivables (2009 - 2026)
Johnson & Johnson (JNJ) posted Receivables of $19.0 billion for Q2 2026, up 7.48% sequentially from $17.7 billion in Q1 2026, and up 6.72% YoY from $17.8 billion in Q2 2025.
Johnson & Johnson (JNJ) Receivables (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Receivables for 18 years, with the latest figure at $19.0 billion in Q2 2026.
- Quarterly Receivables rose 6.72% year-over-year to $19.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $19.0 billion (up 6.72% YoY) and the FY2025 annual result came in at $17.2 billion, up 15.74% from the prior year.
- Receivables grew to $19.0 billion in Q2 2026 per JNJ's latest filing, from $17.7 billion in the prior quarter.
- Over five years, Receivables peaked at $19.0 billion in Q2 2026 and troughed at $14.0 billion in Q1 2023.
- A 5-year average of $16.2 billion and a median of $16.0 billion in 2025 frame the typical range for Receivables.
- The sharpest annual moves came in 2024 and 2025: Receivables slipped 8.59% in 2024, then grew 15.74% in 2025.
- Over 5 years, Receivables stood at $15.9 billion in 2022, then dropped by 6.4% to $14.9 billion in 2023, then decreased by 0.21% to $14.8 billion in 2024, then rose by 15.74% to $17.2 billion in 2025, then advanced by 10.87% to $19.0 billion in 2026.
- According to Business Quant data, Receivables over the past three periods registered $19.0 billion, $17.7 billion, and $17.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 10.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 19.05 Bn |
| Mar 29, 2026 | 17.72 Bn |
| Dec 28, 2025 | 17.18 Bn |
| Sep 28, 2025 | 17.61 Bn |
| Jun 29, 2025 | 17.85 Bn |
| Mar 30, 2025 | 16.02 Bn |
| Dec 29, 2024 | 14.84 Bn |
| Sep 29, 2024 | 16.17 Bn |
| Jun 30, 2024 | 15.79 Bn |
| Mar 31, 2024 | 14.95 Bn |
| Dec 31, 2023 | 14.87 Bn |
| Oct 1, 2023 | 14.80 Bn |
| Jul 2, 2023 | 16.78 Bn |
| Apr 2, 2023 | 16.35 Bn |
| Jan 1, 2023 | 14.04 Bn |
| Oct 2, 2022 | 15.89 Bn |
| Jul 3, 2022 | 16.14 Bn |
| Apr 3, 2022 | 15.59 Bn |
| Jan 2, 2022 | 15.28 Bn |
| Oct 3, 2021 | 14.91 Bn |